In contrast, those with detectable ctDNA will progress with the full six cycles. The trial will also explore end of therapy ...

Early measurable residual disease clearance is linked to better outcomes in acute myeloid leukemia, study suggests.

A multivariate analysis confirmed the independent prognostic significance of both landmark and longitudinal MRD.

US patent No. 12,215,391 relates to Myriad’s proprietary automated methods of MRD analysis. Specifically, the claims are relevant to certain MRD methods that are performed via an automation ...

In the continuing evolution of personalized medicine, a new Yale study has found evidence to support the value of a tool that ...

while patients with detectable ctDNA will continue with the full six cycles of nivolumab + AVD. End of therapy ctDNA-MRD analysis will also be an exploratory endpoint for the trial.

Enhanced assay granted approval by New York State’s Clinical Lab Evaluation Program (CLEP) for patients with DLBCL clonoSEQ is the only DLBCL MRD ...

The trial will also explore end of therapy ctDNA-MRD analysis as an exploratory endpoint. According to the company, the standard treatment for newly diagnosed advanced cHL patients currently ...